Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
PHC Holdings ¥82.6 billion IPO
We advised the international managers in connection with the IPO and TSE listing
Supernus Pharmaceuticals $450 million acquisition of Adamas Pharmaceuticals
We are advising Lazard as financial adviser to Adamas
Securities litigation victory for Synergy Pharmaceuticals officers and directors
We secured a total victory for the clients, with all claims against them dismissed
Inventiva at-the-market offering
We advised the sales agent on the SEC-registered offering of ADSs
Broncus Holding HK$1.55 billion IPO
We advised Broncus on its IPO and HKEX listing
Eli Lilly €1.8 billion and £250 million notes offering
The investment-grade offering included the company’s inaugural sustainability bonds
Maravai LifeSciences $1 billion secondary offering
The shares are listed on the Nasdaq Global Select Market
PerkinElmer $2.3 billion senior notes offering
We advised the underwriters on the investment-grade debt offering
MultiPlan $1.05 billion notes offering and $1.775 billion credit facility
We advised the initial purchasers on the secured high-yield debt offering and the lead arrangers on the new credit agreement
Triple-S Management $900 million acquisition by GuideWell
We are advising Triple-S on the transaction